How big is bioAffinity Technologies, Inc.?

As of Jun 18, bioAffinity Technologies, Inc. has a market capitalization of 7.65 million, with net sales of 8.81 million and a net profit of -9.74 million over the last four quarters.

Market Cap: As of Jun 18, bioAffinity Technologies, Inc. has a market capitalization of 7.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, bioAffinity Technologies, Inc. reported net sales of 8.81 million and a net profit of -9.74 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2.60 million and total assets of 6.51 million.

What does bioAffinity Technologies, Inc. do?

bioAffinity Technologies, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $3 million as of March 2025, with a market cap of $7.65 million. Key metrics include a debt-to-equity ratio of 0.17 and a return on equity of -676.56%.

Overview:<BR>bioAffinity Technologies, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 7.65 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.17 <BR>Return on Equity: -676.56% <BR>Price to Book: 5.31<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold bioAffinity Technologies, Inc.?

Is bioAffinity Technologies, Inc. overvalued or undervalued?

As of February 9, 2024, bioAffinity Technologies, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 5.62 and negative returns on capital and equity, significantly underperforming its peers and the S&P 500 with a year-to-date return of -81.42%.

As of 9 February 2024, the valuation grade for bioAffinity Technologies, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 5.62 and negative EV to EBIT and EV to EBITDA ratios of -0.86 and -0.92, respectively. Additionally, the company's ROCE and ROE are alarmingly low at -573.01% and -676.56%, suggesting severe inefficiencies in generating returns.<BR><BR>In comparison to its peers, bioAffinity's valuation ratios are notably worse; for instance, Nutriband, Inc. has a P/E ratio of -11.6179, while Nephros, Inc. stands out with a very attractive P/E of 31.3944. The stark contrast in performance and valuation metrics reinforces the notion that bioAffinity is not only underperforming but is also at a higher risk compared to its industry counterparts. Furthermore, the company's stock has significantly lagged behind the S&P 500, with a year-to-date return of -81.42% compared to the index's 12.22%, highlighting the challenges it faces in the current market environment.

Is bioAffinity Technologies, Inc. technically bullish or bearish?

As of August 14, 2025, bioAffinity Technologies, Inc. has shifted to a mildly bearish trend, with mixed indicators showing bearish signals from Bollinger Bands and moving averages, while the On-Balance Volume remains bullish, and the stock has significantly underperformed the S&P 500 year-to-date.

As of 14 August 2025, the technical trend for bioAffinity Technologies, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on a weekly basis but bearish on a monthly basis. The Bollinger Bands and KST are bearish on both weekly and monthly time frames, while the moving averages indicate a bearish trend on the daily chart. The Dow Theory shows no trend on a weekly basis and is mildly bearish on a monthly basis. However, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames.<BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -81.42% versus the S&P 500's 12.22%, and a one-year return of -90.71% compared to 17.14% for the index.